IL2 and neoplasm: Recent data have demonstrated that the adoptive transfer of pmel CD8+ Tcm (characterized as CD62L+/CCR7+), or "early effector" T cells (CD62Ldim/CD127+/CCR7+) produced a potent anti-tumor response subsequent to tumor-antigen hgp10025–33 vaccination and high-dose IL-2 therapy in the pmel Tg/B16 therapeutic model [22,35].